Related Experiment Videos
Motion - the available treatments for hepatitis C are cost effective: arguments against the motion
1Department of Medicine, Mayo Clinic and Foundation, Rochester 55905, USA. kim.woong@mayo.edu
Insights
The natural history of hepatitis C virus (HCV) infection is not fully understood, impacting cost-effectiveness of treatment. Further research is needed to clarify HCV
Area of Science:
- Hepatology and Infectious Diseases
- Public Health and Epidemiology
- Health Economics
Background:
- Hepatitis C virus (HCV) infection is common in North America, but its long-term effects on the general population remain unclear.
- Studies show varied outcomes, with some patients developing severe liver disease like cirrhosis and hepatocellular carcinoma, while others have milder disease.
- Current understanding of HCV's natural history is limited by differing study populations and a lack of generalizability from clinical trials.
Purpose of the Study:
- To highlight the uncertainties surrounding the natural history of hepatitis C virus infection.
- To critically evaluate the assumptions and limitations in cost-effectiveness analyses of HCV treatment.
- To emphasize the need for cautious interpretation of HCV treatment cost-effectiveness data.
Main Methods:
- Review of existing cohort-based and referral patient studies on HCV natural history.
- Analysis of limitations in current antiviral therapy trials regarding patient selection and setting generalizability.
- Examination of factors influencing treatment response, including demographics and alcohol consumption.
- Critique of cost-effectiveness models for HCV therapy due to data heterogeneity and underlying assumptions.
Main Results:
- The natural course of hepatitis C virus infection varies significantly among individuals.
- Antiviral therapy effectiveness is influenced by patient demographics and lifestyle factors like alcohol consumption.
- Cost-effectiveness of HCV treatment is difficult to ascertain due to complex variables and model limitations.
- Current antiviral treatments have limitations in effectiveness, cost, and toxicity.
Conclusions:
- Significant uncertainties exist regarding the natural history of hepatitis C virus infection and the true impact of antiviral therapy.
- Cost-effectiveness analyses for HCV treatment should be interpreted with caution, considering the underlying assumptions and data limitations.
- Blind acceptance of HCV treatment cost-effectiveness is not advised given the expense, toxicity, and variable effectiveness of current therapies.
Abstract:
Hepatitis C is a prevalent infection in North America. However, the natural history of hepatitis C virus (HCV) infection in the general population is not fully understood. Available cohort-based studies suggest that only a relative minority of patients develop significant liver disease, such as cirrhosis and/or hepatocellular carcinoma. Other studies, mostly conducted based on referral patients with established disease, portray much more serious consequences of HCV infection. Although a substantial improvement has been made in the treatment for HCV, the overall impact of antiviral therapy in altering the natural course of HCV infection remains uncertain. Therapeutic trials involve narrow selection criteria that would exclude the majority of hepatitis C patients in the community, and are conducted in ideal settings that may not be generalizable to the average practice setting. Demographic groups that are at high risk of developing severe liver disease include older male patients who consume alcohol. In contrast, antiviral therapy is more effective in young and female patients and those who do not drink alcohol. Thus, patients who appear to be successfully treated may not be those for whom clearance of the virus would be beneficial. Cost-effectiveness studies published to date have not been able to fully address the complex and heterogeneous matrix of the factors that influence the natural history of HCV infection and treatment response. In summary, there is a significant degree of uncertainty about many assumptions that are necessary in creating computer models to estimate the cost-effectiveness of HCV therapy. When interpreting the results of cost effectiveness analyses regarding the treatment of HCV infection, it is important to be aware of the underlying assumptions that are incorporated in the model and the data on which they are based. Given these limitations, vis- -vis the expense, toxicity and yet limited effectiveness of the currently available antiviral agents, one should not blindly accept a conclusion that treatment for hepatitis C is cost effective.